Cancer treatment has evolved significantly over the years, with a growing emphasis on targeted therapies that offer more effective and less toxic alternatives to traditional chemotherapy. Rucaparib, a PARP (poly ADP-ribose polymerase) inhibitor, has emerged as a crucial advancement in the treatment of ovarian and prostate cancers, particularly in patients with BRCA mutations or other homologous...